A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Fidarestat sensitized Caco-2 cells to Doxorubicin via increasing cell cycle-dependent cytotoxicity
[post]
2021
unpublished
Objectives: Anthracycline drugs such as Doxorubicin are considered one of the most active, wide-spectrum, and cost-effective drugs that have been used as a therapy for many cancers, but not for colorectal cancer. Recent reports indicate that inhibiting Aldose Reductase increases the sensitivity of human colorectal cancer cells to Doxorubicin. In the present study, we have investigated the effect of using an Aldose Reductase inhibitor (Fidarestat) as an adjuvant drug with Doxorubicin on
doi:10.21203/rs.3.rs-154677/v1
fatcat:o3n5bpzu5rfi7kdllc65ngj6uq